"In addition to LymPro and our NuroPro Parkinsonâ€

Quote:

---

"In addition to LymPro and our NuroPro Parkinson’s diagnostic, we are actively evaluating additional complementary late-stage neurology-focused diagnostic assets that would bolster our diagnostic division and make for a successful ‘spin-out’ while concurrently returning value to our shareholders. We believe we will be able to execute on this strategy in the near-term. "

---

Quote:

---

"As a holding company, our strategy is to acquire undervalued assets, incubate them through critical de-risking milestones and thereafter seek to deliver value to our shareholders through strategic initiatives. We believe we are well positioned to deliver on that promise in the near-term with our diagnostic division, making for the first data point of success of the overall business model and positioning Amarantus to continue this model as we move forward. We believe wholeheartedly in LymPro, and want to ensure that it receives the necessary management focus and commercialization expertise for it to become the gold standard for Alzheimer’s diagnosis. We expect to have updates on this initiative in the near-term. "

---

Quote:

---

"As we expect to soon derive value from our diagnostics division, we believe it will be important to replenish our pipeline with strategically positioned programs that have the potential to deliver significant return on investment for the company, as LymPro has.......................With this strategy we are insulated from enterprise risk from any one program, thereby giving us leverage as we look for additional product opportunities and allowing us to return value to our long-term shareholders either through equity gains or dividends."

---